An international observational prospective study to determine the Cost Of Asthma eXacerbations (COAX)

Respiratory Medicine

Volumn 100, Issue 3, 2006, Pages 434-450

  Lane, Stephen ^a   Molina, Jesus ^b   Plusa, Tadeusz ^c  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b Primary Health Care Unit Pintores   (Spain)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Asthma; Costs; Exacerbations; Primary care; Secondary care

Indexed keywords

AMINOPHYLLINE; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FENOTEROL; HYDROCORTISONE; IPRATROPIUM BROMIDE; METHYLPREDNISOLONE; PREDNISONE; SALBUTAMOL; SALMETEROL XINAFOATE; STEROID; THEOPHYLLINE DERIVATIVE;

ADULT; ARTICLE; ASTHMA; BRAZIL; BULGARIA; CLINICAL OBSERVATION; CROATIA; CZECH REPUBLIC; DENMARK; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; HUNGARY; IRELAND; LATVIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NORWAY; POLAND; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESOURCE ALLOCATION; RUSSIAN FEDERATION; SLOVAKIA; SLOVENIA; SPAIN; UKRAINE;

ACUTE DISEASE; ADULT; AGED; ASTHMA; COSTS AND COST ANALYSIS; DELIVERY OF HEALTH CARE; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS;

EID: 32644435876     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.06.012     Document Type: Article

References (26)

1. Global Initiative for Asthma. NIH publication 02-3659, 2002.
2. British Thoracic Society British guideline on the management of asthma Thorax 58 Suppl 1 2003 i1-i92
3. National Institutes of Health Guidelines for the diagnosis and management of asthma 1997 NIH Bethesda p. 97-4051
4. A.J. Woolcock The problem of asthma worldwide Eur Respir Rev 1 1991 243-246
5. K.F. Rabe P.A. Vermiere J. Soriano W.C. Maier Clinical management of asthma in 1999: The asthma insights and realities in Europe (AIRE) study Eur Respir J 16 2000 802-807
6. P.A. Vermiere K.F. Rable J.B. Soriano W.C. Maier Asthma control and differences in management practices across seven European countries Respir Med 96 2002 142-149
7. G. Hoskins C. McCowan R.G. Neville G.E. Thomas B. Smith S. Silverman Risk factors and costs associated with an asthma attack Thorax 55 2000 19-24
8. P.J. Barnes B. Jonsson J.B. Klim The costs of asthma Eur Respir J 9 1996 636-642
9. P. Lozano P. Fishman M. Von Korff J. Hecht Health care utilisation and cost among children with asthma who were enrolled in a health maintenance organization Pediatrics 88 1997 757-764
10. C.M. Mellis J.K. Peat A.J. Woolcock The cost of asthma: Can it be reduced? Pharmacoeconomics 3 1993 205-219
11. M. Sansonetti S. Pretet P. Guioth L. Denormandie J. Marsac Evaluation du coût medical de l'asthme de l'adulte au cours d'une année de surveillance en milieu hospitalier Rev Mal Resp 6 1989 169-175
12. H.M. Lamb C.R. Culy D. Faulds Inhaled fluticasone propionate Pharmacoeconomics 18 2000 487-510
13. National Asthma Campaign Out in the open. A true picture of asthma in the UK today. Asthma Audit 2001 Asthma J 6 3 special supplement 2001 1-14
14. J.F. Price The management of asthma exacerbations and hospitalizations in young people Eur Respir Rev 58 1998 328-332
15. A. Briggs P. Fenn Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane Health Econ 7 1998 723-740
16. S.D. Sullivan Cost effectiveness of drug interventions Eur Respir Rev 6 1996 116-118
17. J. Serra-Batlles V. Plaza E. Morejon et. al. Costs of asthma according to the degree of severity Eur Respir J 12 1998 1322-1326
18. P. Godard P. Chanez L. Siraudin et. al. Costs of asthma are correlated with severity: A 1-year prospective study Eur Respir J 19 2002 61-67
19. K.R. Chapman A.E. Williams Emergency department attendance and hospitalisation reported in asthma patients considered as mild: Results of a literature review Am J Respir Crit Care Med 169 7 2004 A361
20. J.G. Donahue S.T. Weiss J.M. Livingston M.A. Goetsch D.K. Greineder R. Platt Inhaled steroids and the risk of hospitalisation for asthma JAMA 277 1997 887-891
21. 2-agonists in asthma: clinical and economic implications Clin Immunother 6 1996 489-505
22. G. Shapiro W. Lumry J. Wolfe et. al. Combined salmeterol 50 mcg and fluticasone propionate 250 mcg in the Diskus device for the treatment of asthma Am J Respir Crit Care Med 161 2000 527-534
23. R.A. Pauwels C.-G. Löfdahl D.S. Postma A.E. Tattersfield P. O'Byrne P.J. Barnes et. al. Effect of inhaled formoterol and budesonide on exacerbations of asthma N Engl J Med 337 1997 1405-1411
24. N. Ringdal A.G. Chuchalin L. Chovan et. al. Evaluation of different inhaled combination therapies (EDICT): A randomised, double-blind comparison of Seretide (50/250 mcg bd) via Diskus vs formoterol (12 mcg bd) and budesonide (800 mcg bd) given concurrently (both via Turbuhaler) in patients with moderate to severe asthma Respir Med 96 2002 851-861
25. E.D. Bateman J. Bousquet G.L. Braunstein Is overall asthma control being achieved? A hypothesis-generating study Eur Respir J 17 2001 589-595
26. E.D. Bateman H.A. Boushet J. Bousquet et. al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study Am J Respir Crit Care Med 170 2004 836-844